TNFRSF9 and melanoma: The combined administration of monoclonal antibodies specifically targeted to bind Anti-CD137 proteins and in vitro activated-OT1 CTLs was demonstrated to be able to prevent the melanoma formation in B16-OVA mouse models [7].